Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANUJ BHARGAVA

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1669563052
CMS profile
211123
Location
DES MOINES, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$15,809.66

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANUJ BHARGAVA

NPI 1669563052 · CMS profile ID 211123

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

DES MOINES, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669563052?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANUJ BHARGAVA, NPI 1669563052, CMS profile ID 211123. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669563052?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ANUJ BHARGAVA, NPI 1669563052, CMS profile ID 211123. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669563052?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ANUJ BHARGAVA, NPI 1669563052, CMS profile ID 211123, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1669563052?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $15,809.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–67 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $24.9703/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031267949 CMS
Eli Lilly and Company $13.9303/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031268471 CMS
Eli Lilly and Company $3.9803/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031268473 CMS
Eli Lilly and Company $199.0003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031268475 CMS
Eli Lilly and Company $13.9303/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031268477 CMS
Eli Lilly and Company $3.9803/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031268479 CMS
Eli Lilly and Company $3.9803/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031268481 CMS
Eli Lilly and Company $59.9803/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031268483 CMS
Eli Lilly and Company $24.9903/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031268485 CMS
Eli Lilly and Company $200.6003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031268487 CMS
Eli Lilly and Company $257.3003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031275923 CMS
Eli Lilly and Company $13.9303/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031275925 CMS
Eli Lilly and Company $1,926.0003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031275927 CMS
Eli Lilly and Company $199.0003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031275929 CMS
Eli Lilly and Company $475.0003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031275931 CMS
MannKind Corporation $153.4902/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056255109 CMS
Dexcom, Inc. $17.3201/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054705661 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,076.75 19
PY2021 $147.15 4
PY2022 $1,212.55 41
PY2023 $15,809.66 67
PY2024 $537.92 10
PY2025 $5,161.03 33

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,958,231.43 423
PY2024 Recipient $86,155.00 6
PY2024 Principal investigator $4,215,716.41 321
PY2023 Recipient $2,137.99 7
PY2023 Principal investigator $4,357,402.29 417
PY2022 Recipient $96,905.00 9
PY2022 Principal investigator $2,511,709.23 468
PY2021 Recipient $604.94 3
PY2021 Principal investigator $2,539,988.96 858
PY2020 Recipient $13,104.90 6
PY2020 Principal investigator $2,465,406.24 551
PY2019 Recipient $12,147.83 5
PY2019 Principal investigator $2,249,315.63 274

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

423 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202534581
Principal investigator 1 Sequel Med Tech, LLC $488.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754853
Principal investigator 1 Sequel Med Tech, LLC $170.80 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754859
Principal investigator 1 Sequel Med Tech, LLC $488.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754865
Principal investigator 1 Sequel Med Tech, LLC $170.80 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754872
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754877
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754884
Principal investigator 1 Sequel Med Tech, LLC $8,000.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754889
Principal investigator 1 Sequel Med Tech, LLC $2,800.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754895
Principal investigator 1 Sequel Med Tech, LLC $488.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754901
Principal investigator 1 Sequel Med Tech, LLC $170.80 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754907
Principal investigator 1 Sequel Med Tech, LLC $488.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754914
Principal investigator 1 Sequel Med Tech, LLC $170.80 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754920
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754926
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754932
Principal investigator 1 Sequel Med Tech, LLC $2,223.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754938
Principal investigator 1 Sequel Med Tech, LLC $778.05 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754944
Principal investigator 1 Sequel Med Tech, LLC $488.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754950
Principal investigator 1 Sequel Med Tech, LLC $170.80 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754955
Principal investigator 1 Sequel Med Tech, LLC $488.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754961
Principal investigator 1 Sequel Med Tech, LLC $170.80 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754967
Principal investigator 1 Sequel Med Tech, LLC $488.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754973
Principal investigator 1 Sequel Med Tech, LLC $170.80 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754977
Principal investigator 1 Sequel Med Tech, LLC $488.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754983
Principal investigator 1 Sequel Med Tech, LLC $170.80 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754989
Principal investigator 1 Sequel Med Tech, LLC $488.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754995
Principal investigator 1 Sequel Med Tech, LLC $170.80 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755000
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755004
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755008
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755013
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755019
Principal investigator 1 Sequel Med Tech, LLC $488.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755027
Principal investigator 1 Sequel Med Tech, LLC $170.80 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755033
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755039
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755045
Principal investigator 1 Sequel Med Tech, LLC $488.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755051
Principal investigator 1 Sequel Med Tech, LLC $170.80 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755057
Principal investigator 1 Sequel Med Tech, LLC $488.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755063
Principal investigator 1 Sequel Med Tech, LLC $170.80 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755069
Principal investigator 1 Sequel Med Tech, LLC $488.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755073
Principal investigator 1 Sequel Med Tech, LLC $170.80 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755078
Principal investigator 1 Sequel Med Tech, LLC $2,223.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755084
Principal investigator 1 Sequel Med Tech, LLC $778.05 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755090
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755096
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 12/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243755102
Principal investigator 1 Abbott Laboratories $248.00 12/22/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136854
Principal investigator 1 Abbott Laboratories $72.00 12/22/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136856
Principal investigator 1 Abbott Laboratories $74.00 12/22/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136858
Principal investigator 1 Abbott Laboratories $74.00 12/22/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136860
Principal investigator 1 Abbott Laboratories $19.00 12/22/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136862
Principal investigator 1 Abbott Laboratories $248.00 12/22/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136864
Principal investigator 1 Abbott Laboratories $1.55 12/22/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136866
Principal investigator 1 Abbott Laboratories $17.40 12/22/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136868
Principal investigator 1 Abbott Laboratories $610.00 12/22/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136870
Principal investigator 1 Novo Nordisk AS $395.44 12/22/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
NN9535-4352 No dispute reported 06/30/2026 1213706246
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,268.80 12/09/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791184
Principal investigator 1 Sequel Med Tech, LLC $47.25 12/05/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243754371
Principal investigator 1 Abbott Laboratories $186.00 12/04/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136852
Principal investigator 1 Abbott Laboratories $122.00 12/03/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136848
Principal investigator 1 Abbott Laboratories $248.00 12/03/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136850
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619820
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619822
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619824
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619826
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619828
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619830
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751648
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751653
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751659
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751665
Principal investigator 1 Sequel Med Tech, LLC $2,223.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751669
Principal investigator 1 Sequel Med Tech, LLC $778.05 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751674
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751680
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751686
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751691
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751700
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751706
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751710
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751716
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751723
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751729
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751736
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751741
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751748
Principal investigator 1 Sequel Med Tech, LLC $2,223.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751756
Principal investigator 1 Sequel Med Tech, LLC $778.05 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751762
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751768
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751774
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751780
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751786
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751790
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751796
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751802
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751807
Principal investigator 1 Sequel Med Tech, LLC $2,223.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751815
Principal investigator 1 Sequel Med Tech, LLC $778.05 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751820
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751828
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751834
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751838
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751843
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751848
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751854
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751859
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751863
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751868
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751875
Principal investigator 1 Sequel Med Tech, LLC $488.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751880
Principal investigator 1 Sequel Med Tech, LLC $170.80 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751885
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751890
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 11/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243751896
Principal investigator 1 Abbott Laboratories $6,166.32 11/26/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248160316
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 11/26/2025 Non-covered Recipient Entity
Iowa Diabetes
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220814605
Principal investigator 1 Abbott Laboratories $7,500.00 11/17/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248160250
Principal investigator 1 Abbott Laboratories $122.00 11/14/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136832
Principal investigator 1 Abbott Laboratories $72.00 11/14/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136834
Principal investigator 1 Abbott Laboratories $74.00 11/14/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136836
Principal investigator 1 Abbott Laboratories $74.00 11/14/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136838
Principal investigator 1 Abbott Laboratories $248.00 11/14/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136840
Principal investigator 1 Abbott Laboratories $19.00 11/14/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136842
Principal investigator 1 Abbott Laboratories $17.70 11/14/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136844
Principal investigator 1 Abbott Laboratories $79.00 11/14/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136846
Principal investigator 1 ABBVIE INC. $17,598.96 11/05/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202523063
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619808
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619810
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619812
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619814
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619816
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619818
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748662
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748669
Principal investigator 1 Sequel Med Tech, LLC $2,223.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748675
Principal investigator 1 Sequel Med Tech, LLC $778.05 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748680
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748684
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748690
Principal investigator 1 Sequel Med Tech, LLC $2,223.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748695
Principal investigator 1 Sequel Med Tech, LLC $778.05 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748702
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748707
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748713
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748718
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748724
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748730
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748736
Principal investigator 1 Sequel Med Tech, LLC $2,223.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748743
Principal investigator 1 Sequel Med Tech, LLC $778.05 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748748
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748754
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748761
Principal investigator 1 Sequel Med Tech, LLC $2,223.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748767
Principal investigator 1 Sequel Med Tech, LLC $778.05 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748774
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748781
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748786
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748792
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748798
Principal investigator 1 Sequel Med Tech, LLC $2,223.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748803
Principal investigator 1 Sequel Med Tech, LLC $778.05 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748810
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748816
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748822
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748828
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748834
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748840
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748845
Principal investigator 1 Sequel Med Tech, LLC $2,223.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748851
Principal investigator 1 Sequel Med Tech, LLC $778.05 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748858
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748864
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748870
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748875
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748882
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748887
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748893
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748899
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748906
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748913
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748919
Principal investigator 1 Sequel Med Tech, LLC $488.00 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748923
Principal investigator 1 Sequel Med Tech, LLC $170.80 10/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243748927
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,384.80 10/30/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791182
Principal investigator 1 Abbott Laboratories $186.00 10/27/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136818
Principal investigator 1 Abbott Laboratories $496.00 10/27/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136820
Principal investigator 1 Abbott Laboratories $61.00 10/27/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136822
Principal investigator 1 Abbott Laboratories $13.95 10/27/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136824
Principal investigator 1 Abbott Laboratories $1.40 10/27/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136826
Principal investigator 1 Abbott Laboratories $40.17 10/27/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136828
Principal investigator 1 Abbott Laboratories $7.59 10/27/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136830
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 10/27/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619832
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 10/27/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619834
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
Iowa Diabetes
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220768901
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Iowa Diabetes
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220768903
Principal investigator 1 Abbott Laboratories $7.99 10/14/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136816
Principal investigator 1 Abbott Laboratories $216.00 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136764
Principal investigator 1 Abbott Laboratories $222.00 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136766
Principal investigator 1 Abbott Laboratories $222.00 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136768
Principal investigator 1 Abbott Laboratories $38.00 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136770
Principal investigator 1 Abbott Laboratories $610.00 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136772
Principal investigator 1 Abbott Laboratories $210.00 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136774
Principal investigator 1 Abbott Laboratories $4.65 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136776
Principal investigator 1 Abbott Laboratories $492.00 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136778
Principal investigator 1 Abbott Laboratories $30.98 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136780
Principal investigator 1 Abbott Laboratories $237.00 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136782
Principal investigator 1 Abbott Laboratories $960.00 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136784
Principal investigator 1 Abbott Laboratories $2,723.66 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136786
Principal investigator 1 Abbott Laboratories $320.85 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136788
Principal investigator 1 Abbott Laboratories $17.40 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136790
Principal investigator 1 Abbott Laboratories $82.50 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136792
Principal investigator 1 Abbott Laboratories $26.25 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136794
Principal investigator 1 Abbott Laboratories $9.00 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136796
Principal investigator 1 Abbott Laboratories $13.00 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136798
Principal investigator 1 Abbott Laboratories $58.50 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136800
Principal investigator 1 Abbott Laboratories $211.20 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136802
Principal investigator 1 Abbott Laboratories $28.56 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136804
Principal investigator 1 Abbott Laboratories $171.30 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136806
Principal investigator 1 Abbott Laboratories $17.70 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136808
Principal investigator 1 Abbott Laboratories $555.00 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136810
Principal investigator 1 Abbott Laboratories $29,999.40 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136812
Principal investigator 1 Abbott Laboratories $36.75 10/13/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136814
Principal investigator 1 ABBVIE INC. $14,652.12 10/09/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515975
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619796
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619798
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619800
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619802
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619804
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619806
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 09/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243746996
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 09/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243747002
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 09/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243747007
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 09/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243747014
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 09/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243747022
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 09/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243747028
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 09/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243747035
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 09/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243747041
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 09/24/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619786
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 09/24/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619788
Principal investigator 1 Boehringer Ingelheim International GmbH $1,022.00 09/24/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619790
Principal investigator 1 Boehringer Ingelheim International GmbH $442.20 09/24/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619792
Principal investigator 1 Boehringer Ingelheim International GmbH $27.84 09/24/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619794
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/23/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791180
Principal investigator 1 Sequel Med Tech, LLC $54.27 09/23/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243746612
Principal investigator 1 Novo Nordisk AS $1,965.94 09/19/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
NN9535-4352 No dispute reported 06/30/2026 1213799344
Principal investigator 1 Sequel Med Tech, LLC $20.00 09/19/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243746606
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,114.90 09/18/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791178
Principal investigator 1 ABBVIE INC. $26,124.84 09/04/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509112
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619748
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619750
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619752
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619754
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619756
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619774
Principal investigator 1 Sequel Med Tech, LLC $66.77 09/01/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243746596
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 08/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243745600
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 08/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243745607
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 08/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243745612
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 08/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243745617
Principal investigator 1 Sequel Med Tech, LLC $3,200.00 08/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243745623
Principal investigator 1 Sequel Med Tech, LLC $1,120.00 08/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243745630
Principal investigator 1 Eli Lilly and Company $6,100.00 08/28/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187881272
Principal investigator 1 Novo Nordisk AS $877.29 08/22/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
NN9535-4352 No dispute reported 06/30/2026 1213803664
Principal investigator 1 ABBVIE INC. $36,811.88 08/06/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502963
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $23,995.10 08/06/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791176
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619738
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619740
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619742
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619744
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619746
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 08/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619768
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619772
Principal investigator 1 Sequel Med Tech, LLC $8,000.00 07/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243745046
Principal investigator 1 Sequel Med Tech, LLC $2,800.00 07/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243745050
Principal investigator 1 Boehringer Ingelheim International GmbH $104.94 07/28/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619776
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 07/28/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619778
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 07/28/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619780
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 07/28/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619782
Principal investigator 1 Boehringer Ingelheim International GmbH $35.88 07/28/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619784
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18.00 07/28/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791170
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $600.00 07/25/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791168
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20.00 07/25/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791172
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $570.00 07/22/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791174
Principal investigator 1 Abbott Laboratories $740.00 07/21/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136762
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $95.00 07/19/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791166
Principal investigator 1 Novo Nordisk AS $1,180.69 07/18/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
NN9535-4352 No dispute reported 06/30/2026 1213819195
Principal investigator 1 Abbott Laboratories $52.50 07/17/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136748
Principal investigator 1 Abbott Laboratories $1,628.00 07/16/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136740
Principal investigator 1 Abbott Laboratories $1,932.92 07/16/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136742
Principal investigator 1 Abbott Laboratories $310.50 07/16/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136744
Principal investigator 1 Abbott Laboratories $21,956.00 07/16/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136746
Principal investigator 1 Abbott Laboratories $18.00 07/16/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136750
Principal investigator 1 Abbott Laboratories $8.00 07/16/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136752
Principal investigator 1 Abbott Laboratories $36.00 07/16/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136754
Principal investigator 1 Abbott Laboratories $140.80 07/16/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136756
Principal investigator 1 Abbott Laboratories $47.60 07/16/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136758
Principal investigator 1 Abbott Laboratories $48.00 07/16/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136760
Principal investigator 1 ABBVIE INC. $5,000.00 07/15/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202498270
Principal investigator 1 Dexcom, Inc. $1,800.00 07/14/2025 Non-covered Recipient Entity
Iowa Diabetes & Endocrinology Research Center
Potential outcomes of continuous glucose monitors in low income patients with type 2 diabetes not on insulin therapy. No dispute reported 06/30/2026 1250961764
Principal investigator 1 Eli Lilly and Company $3,500.00 07/14/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187881278
Principal investigator 1 ABBVIE INC. $13,381.38 07/02/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495721
Principal investigator 1 Novo Nordisk AS $2,000.00 07/02/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH CENTER
NN9535-4801 No dispute reported 06/30/2026 1213743709
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619758
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619760
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619762
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619764
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619766
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619770
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,221.30 06/25/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791164
Principal investigator 1 Novo Nordisk AS $1,000.00 06/25/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH CENTER
NN9535-4801 No dispute reported 06/30/2026 1213723167
Principal investigator 1 Novo Nordisk AS $2,504.00 06/25/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH CENTER
NN9535-4801 No dispute reported 06/30/2026 1213728376
Principal investigator 1 Novo Nordisk AS $386.44 06/25/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
NN9535-4352 No dispute reported 06/30/2026 1213760726
Principal investigator 1 Medtronic, Inc. $5,150.00 06/17/2025 Non-covered Recipient Entity
Iowa Diabetes And Endocrinology Research Center Plc.
CIP341 IMPACT2 No dispute reported 06/30/2026 1192323149
Principal investigator 1 ABBVIE INC. $44,183.50 06/03/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202489203
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619720
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619722
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619724
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619726
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619728
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619730
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 05/27/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619732
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 05/27/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619734
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 05/27/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619736
Principal investigator 1 Madrigal Pharmaceuticals $5,350.00 05/26/2025 Non-covered Recipient Entity
IOWA DIABETES & ENDOCRINOLOGY RESEARCH
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248244505
Principal investigator 1 Madrigal Pharmaceuticals $500.00 05/26/2025 Non-covered Recipient Entity
IOWA DIABETES & ENDOCRINOLOGY RESEARCH
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248244509
Principal investigator 1 Madrigal Pharmaceuticals $2,000.00 05/26/2025 Non-covered Recipient Entity
IOWA DIABETES & ENDOCRINOLOGY RESEARCH
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248244513
Principal investigator 1 Medtronic, Inc. $300.00 05/23/2025 Non-covered Recipient Entity
Iowa Diabetes And Endocrinology Research Center Plc.
CIP341 IMPACT2 No dispute reported 06/30/2026 1192323147
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,699.60 05/09/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791162
Principal investigator 1 ABBVIE INC. $21,018.43 05/07/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202484121
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619708
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619710
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619712
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619714
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619716
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619718
Principal investigator 1 Sequel Med Tech, LLC $4,000.00 04/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243743421
Principal investigator 1 Sequel Med Tech, LLC $1,400.00 04/30/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH PLC
Innovative Automated Insulin Delivery System for T2D No dispute reported 06/30/2026 1243743427
Principal investigator 1 Abbott Laboratories $1,420.80 04/24/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136718
Principal investigator 1 Abbott Laboratories $1,757.20 04/24/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136720
Principal investigator 1 Abbott Laboratories $310.50 04/24/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136722
Principal investigator 1 Abbott Laboratories $19,960.00 04/24/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136724
Principal investigator 1 Abbott Laboratories $52.50 04/24/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136726
Principal investigator 1 Abbott Laboratories $18.00 04/24/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136728
Principal investigator 1 Abbott Laboratories $8.00 04/24/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136730
Principal investigator 1 Abbott Laboratories $36.00 04/24/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136732
Principal investigator 1 Abbott Laboratories $140.80 04/24/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136734
Principal investigator 1 Abbott Laboratories $47.60 04/24/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136736
Principal investigator 1 Abbott Laboratories $64.80 04/24/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136738
Principal investigator 1 Novo Nordisk AS $166.00 04/23/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RESEARCH CENTER
NN9535-4801 No dispute reported 06/30/2026 1213737147
Principal investigator 1 Novo Nordisk AS $511.76 04/21/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
NN9535-4352 No dispute reported 06/30/2026 1213741967
Principal investigator 1 Novo Nordisk AS $1,580.63 04/21/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
NN9535-4352 No dispute reported 06/30/2026 1213838946
Principal investigator 1 Eli Lilly and Company $10,843.00 04/15/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187882782
Principal investigator 1 Eli Lilly and Company $425.00 04/14/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) No dispute reported 06/30/2026 1187882544
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,858.90 04/11/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791160
Principal investigator 1 Dexcom, Inc. $10,000.00 04/08/2025 Non-covered Recipient Entity
Iowa Diabetes & Endocrinology Research Center
Potential outcomes of continuous glucose monitors in low income patients with type 2 diabetes not on insulin therapy. No dispute reported 06/30/2026 1250961760
Principal investigator 1 Eli Lilly and Company $6,650.00 04/07/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) No dispute reported 06/30/2026 1187882542
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619696
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619698
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619700
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619702
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619704
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619706
Principal investigator 1 Novo Nordisk AS $23,550.70 03/31/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
EX9924-4473 No dispute reported 06/30/2026 1213764496
Principal investigator 1 Eli Lilly and Company $6,950.00 03/28/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) No dispute reported 06/30/2026 1187884986
Principal investigator 1 Novo Nordisk AS $4,000.00 03/28/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
EX9924-4473 No dispute reported 06/30/2026 1213800466
Principal investigator 1 Abbott Laboratories $1,458.90 03/27/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248136708
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $32,971.65 03/24/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791158
Principal investigator 1 Eli Lilly and Company $113.20 03/17/2025 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187871797
Principal investigator 1 ABBVIE INC. $18,422.03 03/07/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202461353
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619676
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619678
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619680
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619682
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619684
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619686
Principal investigator 1 Boehringer Ingelheim International GmbH $663.30 02/25/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619692
Principal investigator 1 Dexcom, Inc. $3,400.00 02/25/2025 Non-covered Recipient Entity
Iowa Diabetes & Endocrinology Research Center
MULTI-SESSION FEASIBILITY STUDY OF THE DEXCOM G7 DELTA CONTINUOUS GLUCOSE MONITORING (CGM) SENSOR IN ADULT AND PEDIATRIC SUBJECTS No dispute reported 06/30/2026 1250961766
Principal investigator 1 Novo Nordisk AS $2,000.00 02/21/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
EX9924-4473 No dispute reported 06/30/2026 1213780534
Principal investigator 1 Novo Nordisk AS $807.75 02/21/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
NN9535-4352 No dispute reported 06/30/2026 1213792643
Principal investigator 1 Novo Nordisk AS $511.76 02/21/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
NN9535-4352 No dispute reported 06/30/2026 1213824064
Principal investigator 1 Eli Lilly and Company $763.46 02/17/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187881274
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,076.35 02/13/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791156
Principal investigator 1 Eli Lilly and Company $102,219.00 02/11/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187884766
Principal investigator 1 Dexcom, Inc. $3,400.00 02/04/2025 Non-covered Recipient Entity
Iowa Diabetes & Endocrinology Research Center
MULTI-SESSION FEASIBILITY STUDY OF THE DEXCOM G7 DELTA CONTINUOUS GLUCOSE MONITORING (CGM) SENSOR IN ADULT AND PEDIATRIC SUBJECTS No dispute reported 06/30/2026 1250961768
Principal investigator 1 Eli Lilly and Company $47,204.00 02/04/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES No dispute reported 06/30/2026 1187885180
Principal investigator 1 Eli Lilly and Company $200.00 02/03/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) No dispute reported 06/30/2026 1187883936
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619664
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619666
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619668
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619670
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619672
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619674
Principal investigator 1 Eli Lilly and Company $379.56 01/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187882546
Principal investigator 1 Eli Lilly and Company $799.60 01/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187885182
Principal investigator 1 Eli Lilly and Company $4,278.32 01/31/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187885184
Principal investigator 1 Medtronic, Inc. $958.00 01/31/2025 Non-covered Recipient Entity
Iowa Diabetes And Endocrinology Research Center Plc.
CIP341 IMPACT2 No dispute reported 06/30/2026 1192323145
Principal investigator 1 Novo Nordisk AS $1,177.33 01/31/2025 Non-covered Recipient Entity
MERCYONE DES MOINES DIABETES AND ENDOCRINOLOGY
NN9535-4352 No dispute reported 06/30/2026 1213736329
Principal investigator 1 Eli Lilly and Company $7,692.49 01/28/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187883128
Principal investigator 1 Boehringer Ingelheim International GmbH $1.24 01/27/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619688
Principal investigator 1 Boehringer Ingelheim International GmbH $1.16 01/27/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619690
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,023.05 01/27/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791154
Principal investigator 1 Eli Lilly and Company $85,449.00 01/27/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187883134
Principal investigator 1 Eli Lilly and Company $940.90 01/27/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187884034
Principal investigator 1 Eli Lilly and Company $5,600.00 01/27/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A STUDY OF TIRZEPATIDE (LY3298176) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES SWITCHING FROM DULAGLUTIDE (SURPASS-SWITCH) (SURPASS-SWITCH) No dispute reported 06/30/2026 1187884768
Principal investigator 1 Eli Lilly and Company $1,612.18 01/27/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION AND RESEARCH COOP
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187887526
Principal investigator 1 Dexcom, Inc. $615.00 01/23/2025 Non-covered Recipient Entity
Iowa Diabetes & Endocrinology Research Center
Potential outcomes of continuous glucose monitors in low income patients with type 2 diabetes not on insulin therapy. No dispute reported 06/30/2026 1250961762
Principal investigator 1 Eli Lilly and Company $1,668.18 01/22/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187884770
Principal investigator 1 Eli Lilly and Company $48,513.00 01/21/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187881264
Principal investigator 1 Eli Lilly and Company $792.63 01/21/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187882450
Principal investigator 1 Eli Lilly and Company $38,426.00 01/21/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187883132
Principal investigator 1 Eli Lilly and Company $229,853.00 01/21/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187884984
Principal investigator 1 Eli Lilly and Company $79,589.00 01/21/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187885178
Principal investigator 1 Abbott Laboratories $10.56 01/20/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136710
Principal investigator 1 Abbott Laboratories $17.68 01/20/2025 Non-covered Recipient Entity
Iowa Diabetes & Endo Research Center
ISM2305001A--CGM Comparison Study No dispute reported 06/30/2026 1248136712
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,770.50 01/17/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791146
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24.00 01/10/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791148
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $228.00 01/10/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791150
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8.00 01/10/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220791152
Principal investigator 1 Eli Lilly and Company $6,676.26 01/09/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187881270
Principal investigator 1 Eli Lilly and Company $878.19 01/09/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187883938
Principal investigator 1 Dexcom, Inc. $9,899.00 01/07/2025 Non-covered Recipient Entity
Iowa Diabetes & Endocrinology Research Center
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM PROTOCOL No dispute reported 06/30/2026 1250961770
Principal investigator 1 Eli Lilly and Company $75,157.00 01/07/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187881266
Principal investigator 1 Eli Lilly and Company $45,112.00 01/07/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187881268
Principal investigator 1 Eli Lilly and Company $373,768.00 01/07/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187882540
Principal investigator 1 Eli Lilly and Company $49,500.00 01/07/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187884988
Principal investigator 1 Eli Lilly and Company $9.30 01/03/2025 Non-covered Recipient Entity
IOWA DIABETES AND ENDOCRINOLOGY RSRCH CNTR
A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES No dispute reported 06/30/2026 1187882448
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619654
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619656
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619658
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619660
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619662
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Mercyone Des Moines Diabetes And Endocrinology Care
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220619694